TVTX241220C15000
- 4.10
- +0.20+5.13%
Travere Therapeutic Newsroom
Travere Therapeutics (TVTX) Gets a Buy From J.P. Morgan
Travere Therapeutics Is Maintained at Neutral by Piper Sandler
Travere Therapeutics Analyst Ratings
Piper Sandler Maintains Travere Therapeutic(TVTX.US) With Hold Rating, Raises Target Price to $22
Piper Sandler Reaffirms Their Hold Rating on Travere Therapeutics (TVTX)
TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $20 to $33
Travere Therapeutics Is Maintained at Sector Outperform by Scotiabank
Travere Therapeutics Price Target Raised to $27.00/Share From $23.00 by Scotiabank
Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $20
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $20 to $33
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $22
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating
Evercore Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $30
Evercore ISI Sticks to Its Buy Rating for Travere Therapeutics (TVTX)
Wells Fargo Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $27
Travere Therapeutics Analyst Ratings
Wells Fargo Upgrades Travere Therapeutic(TVTX.US) to Buy Rating, Announces Target Price $27
Wells Fargo Upgrades Travere Therapeutics to Overweight From Equalweight, Adjusts Price Target to $27 From $9
Scotiabank Initiates Travere Therapeutics at Sector Outperform With $23 Price Target